215 related articles for article (PubMed ID: 12746772)
1. Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii.
Urban C; Segal-Maurer S; Rahal JJ
Clin Infect Dis; 2003 May; 36(10):1268-74. PubMed ID: 12746772
[TBL] [Abstract][Full Text] [Related]
2. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study.
Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC
Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460
[TBL] [Abstract][Full Text] [Related]
3. [Successful treatment of a patient with multidrug resistant Acinetobacter baumannii meningitis with high dose ampicillin-sulbactam].
Sayin Kutlu S; Saçar S; Süzer T; Cevahir N; Okke D; Dirgen Caylak S; Turgut H
Mikrobiyol Bul; 2008 Apr; 42(2):353-8. PubMed ID: 18697435
[TBL] [Abstract][Full Text] [Related]
4. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
5. Annual trends in antibiotic resistance of nosocomial Acinetobacter baumannii strains and the effect of synergistic antibiotic combinations.
Tatman-Otkun M; Gürcan S; Ozer B; Shokrylanbaran N
New Microbiol; 2004 Jan; 27(1):21-8. PubMed ID: 14964402
[TBL] [Abstract][Full Text] [Related]
6. Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit.
Holloway KP; Rouphael NG; Wells JB; King MD; Blumberg HM
Ann Pharmacother; 2006 Nov; 40(11):1939-45. PubMed ID: 17018688
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Acinetobacter infections.
Michalopoulos A; Falagas ME
Expert Opin Pharmacother; 2010 Apr; 11(5):779-88. PubMed ID: 20210684
[TBL] [Abstract][Full Text] [Related]
8. [Antibiotic resistance of Acinetobacter baumannii isolates: data from Ibni Sina Hospital for the year 2002].
Akan OA
Mikrobiyol Bul; 2003 Oct; 37(4):241-6. PubMed ID: 14748260
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of cefepime combined with sulbactam against clinical isolates of carbapenem-resistant Acinetobacter spp.
Tong W; Wang R; Chai D; Li Z; Pei F
Int J Antimicrob Agents; 2006 Nov; 28(5):454-6. PubMed ID: 16987639
[TBL] [Abstract][Full Text] [Related]
10. A multifaceted intervention to reduce pandrug-resistant Acinetobacter baumannii colonization and infection in 3 intensive care units in a Thai tertiary care center: a 3-year study.
Apisarnthanarak A; Pinitchai U; Thongphubeth K; Yuekyen C; Warren DK; Fraser VJ;
Clin Infect Dis; 2008 Sep; 47(6):760-7. PubMed ID: 18684100
[TBL] [Abstract][Full Text] [Related]
11. Synergistic activities between carbapenems and other antimicrobial agents against Acinetobacter baumannii including multidrug-resistant and extensively drug-resistant isolates.
Kiratisin P; Apisarnthanarak A; Kaewdaeng S
Int J Antimicrob Agents; 2010 Sep; 36(3):243-6. PubMed ID: 20541913
[TBL] [Abstract][Full Text] [Related]
12. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians.
Jain R; Danziger LH
Ann Pharmacother; 2004 Sep; 38(9):1449-59. PubMed ID: 15280512
[TBL] [Abstract][Full Text] [Related]
13. Restricting the use of ampicillin-sulbactam.
Zavascki AP; Sandri AM
J Hosp Infect; 2004 Feb; 56(2):165-6. PubMed ID: 15019231
[No Abstract] [Full Text] [Related]
14. Preventing strategy of multidrug-resistant Acinetobacter baumanii susceptible only to colistin in cardiac surgical intensive care units.
Mastoraki A; Douka E; Kriaras I; Stravopodis G; Saroglou G; Geroulanos S
Eur J Cardiothorac Surg; 2008 Jun; 33(6):1086-90. PubMed ID: 18339553
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for multi-drug resistant Acinetobacter baumannii nosocomial infection.
Surasarang K; Narksawat K; Danchaivijitr S; Siripanichgon K; Sujirarat D; Rongrungrueng Y; Kiratisin P
J Med Assoc Thai; 2007 Aug; 90(8):1633-9. PubMed ID: 17926995
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic options for Acinetobacter baumannii infections.
Vila J; Pachón J
Expert Opin Pharmacother; 2008 Mar; 9(4):587-99. PubMed ID: 18312160
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment of skin and soft tissue infection due to carbapenem-resistant Acinetobacter baumannii by ampicillin-sulbactam and meropenem combination therapy.
Hiraki Y; Yoshida M; Masuda Y; Inoue D; Tsuji Y; Kamimura H; Karube Y; Takaki K; Kawano F
Int J Infect Dis; 2013 Dec; 17(12):e1234-6. PubMed ID: 23791858
[TBL] [Abstract][Full Text] [Related]
18. Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.
Maragakis LL; Perl TM
Clin Infect Dis; 2008 Apr; 46(8):1254-63. PubMed ID: 18444865
[TBL] [Abstract][Full Text] [Related]
19. [Multidrug resistant Acinetobacter baumannii].
Nemec A
Klin Mikrobiol Infekc Lek; 2008 Oct; 14(5):162-7. PubMed ID: 19051163
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
